VEGFR-2 expression in human melanoma: revised assessment.

Area of Science:

• Oncology
• Molecular Biology
• Immunohistochemistry

Background:

• Vascular Endothelial Growth Factor (VEGF) is implicated in melanoma growth via its receptor, VEGFR-2.
• Previous studies suggested high VEGFR-2 expression in melanoma, indicating potential benefit from anti-VEGF therapy.
• Antibody specificity issues may have led to overestimation of VEGFR-2 expression in prior research.

Purpose of the Study:

• To accurately determine the prevalence of VEGFR-2 expression in human melanoma specimens.
• To validate the specificity of commercial antibodies used for VEGFR-2 detection in melanoma.
• To reassess the potential benefit of anti-VEGF therapy for melanoma patients based on VEGFR-2 expression levels.

Main Methods:

• Evaluation of 167 human melanoma specimens using tissue microarrays.
• Comparison of two commercial antibodies (A-3 and 55B11) for VEGFR-2 immunostaining.
• Validation of antibody specificity using immunoblotting and immunohistochemistry with siRNA knockdown and gene overexpression in melanoma cell lines.

Main Results:

• Antibody A-3 showed high staining (79%), but exhibited significant nonspecific binding.
• Antibody 55B11 demonstrated specific staining in only 7% of melanoma specimens.
• Validation experiments confirmed 55B11 as a more specific antibody, with VEGFR-2 expression below 10% in melanoma.

Conclusions:

• The majority of melanoma cells express low or undetectable levels of VEGFR-2.
• Previous estimates of VEGFR-2 expression in melanoma are likely inflated due to antibody cross-reactivity.
• Most melanoma patients are unlikely to benefit from anti-VEGF therapies targeting the antiproliferative effects of VEGFR-2.